In the present study it was investigated whether and by which are encoded by genes located respectively on chromosomes mechanisms the co-administration of interleukin-3 (IL-3) and 17 and 3. Topo II␣ expression varies during the cell cycle, the P-glycoprotein blocker PSC 833 can augment mitoxantrone whereas levels of topo II␤ remain constant in most cell lines. shown that a relation exists between G-CSF induced AML cell lines.
Materials and methods Introduction

Cell lines
One of the major obstacles in the treatment of patients with acute myeloid leukemia (AML) is the development of multi-
The human growth factor-dependent AML cell lines drug resistance (MDR), which is resistance to a group of natuand GF-D8 23 were cultured in RPMI 1640 medium (FLOW, ral products such as the anthracyclines, vinca-alkaloids and Rockville, MD, USA) supplemented with fetal calf serum (FCS; epidophylotoxins. Several mechanisms have been identified Hyclone, Logan, UT, USA) and recombinant IL-3 (gift Dr SC for this so-called MDR. The most intensively studied MDR Clark, Genetics Institute, Cambridge, MA, USA). For cell mechanism is the overexpression of the MDR-1 gene resulting phenotyping Mo-7 and GF-D8 cells (10 6 /50 l RPMI 1640) in an increased P-glycoprotein (P-gp)-mediated efflux of drugs were incubated with 10 l FITC-labelled mouse monoclonal such as DAU 1 and MX. 2 This resistance mechanism can parantibodies to CD34, CD33, CD15, CD14, or HLA-DR (Becton tially be overcome by P-gp blockers such as verapamil, cycloDickinson, Mountain View, CA, USA), for 30 min at 0°C, sporin A, and the cyclosporin-derivative PSC 833. [3] [4] [5] [6] The mulwashed with RPMI 1640 medium and analyzed. For P-gp tidrug resistance-related protein (MRP) is also involved in detection 10 6 cells (in 50 l RPMI 1640) were incubated with MDR. 7, 8 Overexpression of this protein mediates an increased 10 l of the mouse monoclonal antibody against P-gp 4E3 efflux of drugs such as DAU. 9 Another factor that can be (ITK Diagnostics BV, Uithoorn, The Netherlands) for 30 min involved in MDR is a reduced expression of the drug target, at 0°C, washed twice with RPMI 1640 followed by 30 min the enzyme DNA topoisomerase II. 10, 11 Two isoforms of incubation at 20°C with the second antibody (RAM-FITC, human topo II have been isolated, designated ␣ and ␤ which 1:20; Becton Dickinson). For bcl-2 protein detection, 1.5 × 10 6 cells were resuspended in 2 ml 2% paraformaldehyde. After 10 min incubation on ice, 100 l Triton X-100
Correspondence: E Vellenga, Division of Haematology, Department was added followed by another 10 min incubation on ice.
of Internal Medicine, University Hospital, PO Box 30.001, 9700 RB isotype-matched control antibody was added for 30 min at with 10 ng/ml IL-3. Samples of 10 6 cells were collected at 0 and 24 h and analyzed for DNA content with FACS (n = 3). 4°C. The cells were analyzed on a FACS-Star flow cytometer (Becton Dickinson). Experiments were performed three times.
The percentage of cells in G0/G1, G2, and S-phase were calculated.
Growth curves Cytotoxicity assays
Cells were cultured with variable doses of FCS (0-10%) to define the optimal proliferative response of Mo-7 and GF-D8 Cytotoxicity was measured with the microculture tetrazolium cells to IL-3 stimulation. In the absence of IL-3, Mo-7 and GFtest (MTT) as described earlier. 24 Per microculture well (96 D8 cells did not proliferate with 1% and 0.1% FCS, respectwell microtiter well plates; Nunc, Roskilde, Denmark) 0.1 ml ively. Lower concentrations of FCS resulted in cell death.
was used. The cytotoxicity was analyzed for increasing conThereafter, dose-response curves were performed with varicentrations of DAU (Rhô ne-Poulenc Rorer, Amstelveen, The able concentrations of IL-3 (0-10 ng/ml, n = 3). Optimal proNetherlands) and MX (Lederle, Etten-Leur, The Netherlands) liferation in both cell lines was observed with 10 ng/ml IL-3.
in the presence or absence of IL-3, and PSC 833. Based on these data Mo-7 cells were cultured with 1% FCS First, Mo-7 cells (1% FCS) and GF-D8 cells (0.1% FCS) were and 10 ng/ml IL-3 which resulted in a cell doubling time of preincubated for 24 h with or without 10 ng/ml IL-3. There-34 h. The GF-D8 cells were cultured with 0.1% FCS and after, the cells (5 × 10 4 /well for Mo-7 and 5 × 10 5 /well for GF-10 ng/ml IL-3 which resulted in a cell doubling time of 55 h. D8) were incubated 1 h in culture medium with different concentrations of MX or DAU alone or in combination with PSC 833.
Preparation of cell membrane fractions and P-gp 10.0 g/ml PSC 833 were used. Higher doses of PSC 833 washed twice with phosphate-buffered saline (PBS: 0.14 M resulted in cytotoxic effects. Thereafter, cells were washed NaCl, 2.7 mM KCl, 6.4 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 , three times with RPMI 1640 medium with FCS, followed by pH 7.4) and harvested from the culture flasks and subsequent addition of fresh RPMI 1640 medium supplemented with FCS. centrifugation (5000 g) followed by permeabilization by 40-After a 3-day culture period, cells were processed as fold dilution with 1 mM Tris/HCl, pH 7.0; in the presence of described earlier.
24 400 U recombinant Serratia marcescens nuclease (benzonase, The survival of IL-3 preincubated or IL-3 depleted cells that grade II, protease-free; Merck, Darmstadt, Germany). Next, were not incubated with drugs was expressed as 100%. All the cell lysate was centrifuged for 30 min; 100 000 g, 4°C, assays were performed three times each in quadruplicate. and the resulting pellet was suspended in 10 ml of tris/sucrose (TS) buffer (10 mM Tris/HCl, pH 7.4/250 mM sucrose) and homogenized with a Dounce B homogenizer (LGB, Leek, The Cellular MX levels Netherlands), in the presence of 800 U benzonase. The crude membrane fraction was layered on top of a discontinuous Cellular MX levels were determined with FACS as described. 24 sucrose gradient (31% and 38% sucrose (w/w)) and centriMo-7 cells (1% FCS) and GF-D8 cells (0.1% FCS) were prefuged 2 h in a swing-out rotor at 280 000 g, 4°C. The turbid incubated for 24 h with or without 10 ng/ml IL-3. Sublayers at the interfaces (TS/31% and 31/38%) were collected, sequently 1 × 10 6 /ml cells were incubated 1 h at 0°C or 37°C, diluted with TS buffer and centrifuged 30 min at 100 000 g at with 0.0, 0.05, 0.10 and 0.20 M MX for Mo-7 and 0.0, 0.5, 4°C. The resulting pellets were resuspended in TS buffer.
1.0 and 2.0 M MX for GF-D8 cells. Thereafter the cells were Equal amounts of proteins were size-fractioned in a sodium centrifuged 10 min at 0°C. The supernatant was removed, and dodecyl sulphate (SDS)/7.5% polyacrylamide gel. MDR1-P-gp the pellet resuspended in 200 l ice-cold RPMI 1640 medium. was detected with the monoclonal antibody C219 (Centocor,
The fluorescence was measured as described earlier. 24 To Antwerp, Belgium). For the detection enhanced chemilumistudy MX efflux, the cells were resuspended in fresh drug-free nescence (Amersham, Bucks, UK) was used.
RPMI 1640 medium with FCS and subsequently incubated for another hour at 37°C. Cellular MX accumulation was calculated by subtracting the fluorescence values measured at 0°C
Functional MDR activity (auto-fluorescence plus extracellular bound drug) from the corresponding values measured at 37°C. Cellular drug levels For rhodamine 123 (Rh123) efflux study, Mo-7 cells treated measured directly after 1 h incubation with the highest conwith IL-3 were stained with 200 ng/ml Rh123 with or without centration MX, without preincubation with IL-3, was 2 g/ml PSC833 (kindly provided by Sandoz, Basel, expressed as 100%, experiments were performed three times. Switzerland), for 20 min at 37°C. After washing with cold RPMI 1640, cells were incubated in Rh123-free medium with or without 2 g/ml PSC833 for 1 h at 37°C. Untreated RNA preparation and Northern blot analysis cells were included in the assay for autofluorescence. Stained cells were analyzed with FACS-star flow cytometer.
Both cell lines were cultured for 24 h in FCS-containing RPMI 1640 medium, without IL-3. After 0, 0.5, 2, 6, 12, and 24 h of IL-3 stimulation, cells were harvested and total RNA was Cell cycle analysis isolated using the guanidium isothiocyanate/cesium chloride method. Samples (15 g) of total cellular RNA were size fracTo analyze the effect of IL-3 on the cell cycle, Mo-7 and GF-D8 cells were deprived of IL-3 for 24 h followed by incubation tionated on 1.2% agarose gels containing 2.2 M formaldehyde ethidium bromide at 50 V for 3 h. Gels were stained with ethidium bromide (1 g/ml) for 1 h and destained for 2-3 h in cDNA probes were labelled with The paired Student's t-test was used for statistical analysis.
Only P values Ͻ0.05 were considered significant.
Topoisomerase II activity
Mo-7 cells (1% FCS) and GF-D8 cells (0.1% FCS) were preResults incubated without IL-3 for 24 h. Thereafter, the cells were incubated 24 h with or without IL-3, followed by nuclear Cell phenotypes and P-gp expression enzyme extracts preparation. GLC-4 cells 25 were included as control for topo II catalytic activity. Log-phase cells (10 × 10 6 ) were collected and centrifuged at 150 g for 10 min and CD33 and bcl-2 protein were expressed in both cell lines, washed twice with ice-cold PBS. Cell pellets were resuswhereas no expression of CD34, CD15, CD14 or HLA-DR pended in 400 l extraction buffer (10 mM Hepes, pH 7.9, was observed. Evaluation of the P-gp expression with FACS 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol analysis revealed expression of P-gp on GF-D8 cells whereas (DTT), 0.5 mM PMSF) and 25 l nonidet (NP-40, 10%) was no expression was demonstrated on Mo-7 cells (Figure 1a,b) . added. Nuclei were spun down at 16 000 g for 30 s and Western blotting demonstrated however that P-gp protein was extracted for 15 min at 4°C with 50 l ice-cold extraction also present in the Mo-7 cell membranes (Figure 1c ). Morebuffer (20 mM Hepes, pH 7.9, 0.35 mM NaCl, 1 mM EDTA, over the functionality of PgP protein in the Mo-7 cell line 1 mM EGTA, 1 mM DTT, 1 mM PMSF) by severe shaking. The could be demonstrated with Rh 123-efflux in the absence and mixture was spun down at 16 000 g for 5 min at 4°C and presence of PSC (blocking factor 1.19 ± 0.05 (× ± s.d., n = 3)). supernatant with nuclear enzymes was collected. Protein concentrations were determined.
26
Topo II catalytic activity was determined by decatenation Effects of IL-3 on drug cytotoxicity of kinetoplast DNA (kDNA) networks. 27 The standard reaction mixture for the decatenation assay was 50 mM Tris/HCl (pH 7.5, 85 mM KCl, 10 mM MgCl 2 , 0.5 mM dithiothreitol, Figure 2 shows the effects on both cell lines of increasing concentrations of MX or DAU after IL-3 pretreatment or depri-0.5 mM EDTA, bovin serum albumin (BSA, 0.03 mg/ml) and 1 mM ATP. Decatenation of kDNA was carried out by incubatvation (Figure 2 ). IL-3 enhanced the cytotoxic effect of 0.05 M MX (P Ͻ 0.005) and of 0.2 M MX (P Ͻ 0.02) in Moing 5 l nuclear extract containing 4 or 2 g protein in case of Mo-7 and the control cell line GLC-4 and 10 or 5 g pro-7 cells. Also GF-D8 cells became more vulnerable for MX by IL-3 pretreatment. The cytotoxic effect of DAU on Mo-7 cells tein for GF-D8 with 0.1 g kDNA in a final volume of 25 l standard reaction mixture for 30 min at 37°C. Reactions were was enhanced by IL-3 at the 0.4 g/ml (P Ͻ 0.05) and 0.8 g/ml (P Ͻ 0.05) dose. Comparable results were obtained terminated by addition of 5 l 3% SDS, 0.3% bromophenol blue and 30% glycerol. Samples were separated by electrofor GF-D8; at both doses (5.0, 7.5 g/ml) a reduction was observed in cell survival (P Ͻ 0.002 and P Ͻ 0.001). phoresis on 1% agarose in 89 mM Tris-borate (pH 8.3), 2 mM 
Figure 4
Topo II activity of various amounts of nuclear extract (indicated). Point of time (t) 1 represents decatenation assayed after 24 h of IL-3 deprivation, 2 indicates 24 h IL-3 deprivation followed by 24 h stimulation with IL-3. Monocycled kDNA is indicated (M). Lane 1 demonstrates a control reaction mixture to which no nuclear extract had been added.
Figure 3
Kinetics of topo II␣ and topo II␤ mRNA expression in Mo-7 and GF-D8 cells deprived from IL-3 for 24 h (t = 0) and subsequently stimulated with IL-3 for 24 h (t = 24). Densitometric scanning of three separate experiments is shown. Asterisk indicates significant elevation.
mRNA expression did not demonstrate a change in expression after IL-3 stimulation in both cell lines (data not shown). In Effects of IL-3 on MDR-1 and bcl-2 expression addition, no difference in bcl-2 expression was observed in the cell lines after 24 h stimulation with IL-3. After 24 h of Next FACS analysis was performed with P-gp and bcl-2 antibodies to exclude the possibility that the effects were caused IL-3 deprivation, and 24 h of IL-3 stimulation, respectively 86% (±6) and 93% (±2) of the Mo-7 cells were positive for in part by an IL-3-mediated down-regulation of P-gp and bcl-2. No change in P-gp expression was observed on GF-D8 cells bcl-2 (ns). For GF-D8, 90% (±4) of unstimulated and 88% (±4) of the stimulated cells demonstrated bcl-2 expression (ns). in the absence and presence of IL-3. Furthermore, MDR-1 Cellular MX levels lines as a result of IL-3 treatment. In Mo-7 cells treated with 0.5 M MX, 100 vs 101% ± 8 fluorescence intensity was observed after IL-3 deprivation and stimulation respectively Cellular levels and efflux studies were performed to demonstrate whether or not the augmented cytotoxic effects of MX and after 1 h efflux under both conditions MX content was reduced to 70%, regardless of IL-3 stimulation. In GF-D8 cells in the presence of IL-3 were due to a reduced efflux of MX. There was no significant change in MX content in both cell treated with 2.0 M MX after IL-3 deprivation or stimulation, 100 vs 96% ± 4 (ns) after 1 h accumulation and 60% MX conrelated to an increased drug target, the topo II activity, only in the Mo-7 cell line. This is underscored by the fact that an tent was observed respectively after 1 h efflux, indifferent of IL-3 treatment.
increase in the number of cells in S-phase was observed in conjunction with an increased expression of topo II␣ mRNA expression and topo II activity. In the GF-D8 cell line, the IL-3-mediated effects were also present but although the increase Effects of IL-3 on topo II␣ and topo II␤ mRNA expression and topoisomerase II activity in the number of cells in S-phase was significant, the topo II␣ mRNA expression and topo II activity were not. The expression of bcl-2, a protein known to inhibit apoptosis and Northern blot analysis was performed for the topo II␣ and ␤ transcripts to study whether the IL-3-mediated increase in which down-regulation could lead to increasing proliferation 28 or apoptosis in case of severe DNA damage, was not cytotoxicity might be caused by an augmented topo II expression. Topo II␣ and ␤ mRNAs were constitutively affected by IL-3 treatment. These data suggest that an additional mechanism such as different drug targets or efflux expressed in both cell lines. Topo II␣ mRNA expression was increased after 24 h IL-3 stimulation in both cell lines pumps might also be involved. PSC 833 modulated the cytotoxic effects of DAU in both P- (Figure 3) . However, the degree of topo II␣ upregulation was most pronounced in the Mo-7 cell line (25%, P Ͻ 0.05, n = 3).
gp positive cell lines. However, the degree of modulation by PSC 833 was most pronounced in the GF-D8 cell line which No significant change in topo II␤ mRNA was observed in both cell lines. Subsequently cell cycle analysis was performed to also had the highest P-gp expression. Combining PSC 833 with IL-3 resulted in an enhanced cytotoxic effect of DAU in demonstrate whether the degree of Topo II␣ upregulation corresponded with the percentage increase of cells in S-phase. In both cell lines. In the GF-D8 cell line the combination of PSC 833 and IL-3 resulted in an increased cytotoxicity compared the Mo-7 cell line the S-phase cells increased from 4% ± 2 to 24% ± 8 (P Ͻ 0.01, n = 3) after 24 h of IL-3 treatment. In the to the effects of IL-3 and PSC 833 alone. The data indicate that different pathways can be triggered to enhance the effects GF-D8 cell line the increase was 31% ± 3 to 42% ± 3 (P Ͻ 0.01, n = 3). In addition topo II activity was analyzed of cytotoxic agents such as DAU. The data also support the view that a combination of different approaches in clinical after IL-3 treatment (Figure 4 ). Mo-7 cells treated with IL-3 showed a distinct increase in topo II activity. In the GF-D8 trials might be relevant to overcome MDR since in leukemia several mechanisms of MDR are operational. In contrast to cells no increase in topo II activity was observed after IL-3 stimulation.
DAU whereas cell lines resistant to DAU are frequently P-gp posiFinally it was analyzed whether PSC 833 modulates the cytotoxic effects of MX and DAU in the absence or presence of tive. 31, 32 These data suggest that the cellular effects and targets of both compounds are in part different and subsequently IL-3, Mo-7 ( Figure 5a ) and GF-D8 cells (Figure 5b ) were exposed to PSC 833 at variable concentrations in combination have to be modulated in different ways. In summary, the results demonstrate that the co-adminiswith MX. PSC 833 did not modulate the cytotoxic effects of MX in Mo-7 and GF-D8 cells in the absence or presence of tration of IL-3 and PSC 833 can have additive effects on the DAU cytotoxicity in P-gp positive cell lines whereas IL-3 IL-3. Similar experiments were performed with DAU. In contrast to MX, PSC 833 augmented the cytotoxic effects of DAU alone can enhance the effects of MX by increasing topo II activity. in both cell lines. In Mo-7 cells PSC 833 (2 g/ml) increased the cytotoxicity at the highest concentration of DAU (0.8 g/ml) after IL-3 preincubation (62% ± 9 vs 37% ± 3, P Ͻ 0.01, Figure 5a ). Comparable results were obtained with the GF-D8 cell line. PSC 833 enhanced the DAU effect on GF
